A Retrospective, Single-centre, Real-world study to evaluate the safety and efficacy of sodium-glucose co-transporter 2 inhibitor (SGLT2) in patients with Diabetes Mellitus

Trial Profile

A Retrospective, Single-centre, Real-world study to evaluate the safety and efficacy of sodium-glucose co-transporter 2 inhibitor (SGLT2) in patients with Diabetes Mellitus

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs Canagliflozin (Primary) ; Dapagliflozin (Primary) ; Empagliflozin (Primary)
  • Indications Diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 20 Apr 2017 New trial record
    • 04 Apr 2017 Results presented at The 99th Annual Meeting of the Endocrine Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top